IonLyme

Lyme disease: a problem seeking a diagnosis
  • Lyme disease is the fastest growing vector-borne disease in the US according to the CDC. 

  • It is often erroneously considered a regional disease limited to the Mid-Atlantic, Northeastern, and Upper Midwestern regions of the US 

  • Cases have been found in all 50 states

  • It is rapidly spreading into the Southeastern US, the mountain Western states, and into California making it a national problem.

  • Lyme disease is easily treated IF DETECTED WITHIN 10 WEEKS OF EXPOSURE

  • The lack of effective diagnosis Is the largest hurdle to addressing the Lyme disease epidemic

Poor current testing methods
  • ​The current CDC recommended Lyme disease diagnostic test is only 50% effective when treatment is effective.

  • The CDC assay detects antibodies developed after exposure to Lyme disease, or the body’s response to infection, and not the infection itself. 

  • This approach has significant issues

    • Slow production of antibodies results in a high false-negative rates (up to 60%) 

    • It is impossible to differentiate recent exposure for past exposure

      • Once antibody levels reach detectable levels, it remains high for up to a decade

  • CDC test is ineffective in:

    •  patients who are tested < 30 days following infection, 

    • those who have weak or suppressed immune responses. 

  • Identification of an active infection soon after exposure is critical

    • treatment is most effective with 6 weeks of exposure

Ionica's solution: IonLyme
  • IonLyme improves Lyme disease testing in two ways:

    • Detection within the time that treatment is effective

    • Allows differentiation between new and old exposures

  • IonLyme™ directly detects a protein, called Outer Surface Protein A (OspA) present only during active Lyme disease infections. 

  • OspA is found only when an active Lyme case is present. 

  • This change in testing paradigm provides capabilities not currently available to the clinician:

    • Provide accurate detection of Lyme disease within the effective treatment window

    • follow the efficacy of treatment 

    • determine if a patient has been re-infected

IonLyme: How it works
  • The IonLyme assay uses two well established technologies, aptamers​ & Surface Enhanced Raman Scattering (SERS)​, in a cutting edge method.

  • This combination produces a test capable of rapidly and specifically detecting OspA in serum samples obtained from human Lyme disease patients.

Ionica Sciences

McGovern Family Center for Venture Development in the Life Sciences

Cornell University

413 Weill Hall

Ithaca, NY 14853

©2018 by Ionica Sciences. Proudly created with Wix.com